Related references
Note: Only part of the references are listed.TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
Shaw M. Akula et al.
AGING-US (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer
Li Ding et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Przemyslaw Duda et al.
CELLS (2020)
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Luisa F. Escobar-Hoyos et al.
CANCER CELL (2020)
GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells
Przemyslaw Duda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis
Madelaine G. van Mackelenbergh et al.
CANCERS (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling
Fidan Seker et al.
CANCERS (2019)
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
Hiroo Kuroki et al.
SCIENTIFIC REPORTS (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
GSK3 regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer
Geraldine Vidhya Vijay et al.
BREAST CANCER RESEARCH (2019)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Axl inhibitors as novel cancer therapeutic agents
Yingying Shen et al.
LIFE SCIENCES (2018)
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva et al.
CANCER CELL (2018)
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Aslamuzzaman Kazi et al.
NATURE COMMUNICATIONS (2018)
Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells
Aeyung Kim et al.
FRONTIERS IN PHARMACOLOGY (2018)
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
James A. McCubrey et al.
ONCOTARGET (2017)
Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia
Li Ding et al.
JOURNAL OF PATHOLOGY (2017)
A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo
Tsung-Chieh Shih et al.
MOLECULAR CANCER THERAPEUTICS (2017)
NF-B Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers
Paola Poma et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2017)
Gsk3 is a metabolic checkpoint regulator in B cells
Julia Jellusova et al.
NATURE IMMUNOLOGY (2017)
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Knockdown of GSK3β increases basal autophagy and AMPK signalling in nutrient-laden human aortic endothelial cells
Karen A. Weikel et al.
BIOSCIENCE REPORTS (2016)
GSK-3 inhibition overcomes chemoresistance in human breast cancer
Andrey Ugolkov et al.
CANCER LETTERS (2016)
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Sandra Baumgart et al.
MOLECULAR CANCER THERAPEUTICS (2016)
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy
Miguel Angel Pavon et al.
ONCOTARGET (2016)
GSK-3β controls NF-kappaB activity via IKKγ/NEMO
Senad Medunjanin et al.
SCIENTIFIC REPORTS (2016)
Deciphering the role of hedgehog signaling in pancreatic cancer
Dongsheng Gu et al.
JOURNAL OF BIOMEDICAL RESEARCH (2016)
A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP
Crystal Woodard et al.
JOURNAL OF VIROLOGY (2015)
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Manuel Hidalgo et al.
PANCREATOLOGY (2015)
A Systematic Review of the Anticancer Properties of Compounds Isolated from Licorice (Gancao)
Zheng-Hai Tang et al.
PLANTA MEDICA (2015)
Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways Supplementary Issue: Animal Models of Cancer Biology
Julianna Padavano et al.
CANCER GROWTH AND METASTASIS (2015)
Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells
Melissa Sokolosky et al.
CELL CYCLE (2014)
Glycogen synthase kinase-3 (GSK3) controls deoxyglucose-induced mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells
Pronrumpa Ngamsiri et al.
MITOCHONDRION (2014)
Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
J. A. McCubrey et al.
LEUKEMIA (2014)
Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1
S. Shin et al.
ONCOGENE (2014)
Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells
Yanling Zhou et al.
ONCOLOGY REPORTS (2014)
Pancreatic Satellite Cells Derived Galectin-1 Increase the Progression and Less Survival of Pancreatic Ductal Adenocarcinoma
Dong Tang et al.
PLOS ONE (2014)
GSK-3 as potential target for therapeutic irvention in cancer
James A. McCubrey et al.
ONCOTARGET (2014)
Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
Mohamed Rahmani et al.
CANCER RESEARCH (2013)
p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells
Nam Hee Kim et al.
CELL CYCLE (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1-TAB Stabilization and Regulation of Noncanonical NF-κB
Deepali Bang et al.
CANCER DISCOVERY (2013)
GSK-3 and mitochondria in cancer cells
Federica Chiara et al.
FRONTIERS IN ONCOLOGY (2013)
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)
Hisashi Kawazoe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer
Wei Zhou et al.
CANCER LETTERS (2012)
Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1)
Sejeong Shin et al.
CELL CYCLE (2012)
GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) β1-induced senescence
Hae-Ok Byun et al.
EXPERIMENTAL CELL RESEARCH (2012)
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
James A. McCubrey et al.
ONCOTARGET (2012)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey et al.
ONCOTARGET (2012)
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman et al.
AGING-US (2011)
Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway
Vijayalakshmi Thamilselvan et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance
Yunfeng Fu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Convergence of the Mammalian Target of Rapamycin Complex 1-and Glycogen Synthase Kinase 3-β-Signaling Pathways Regulates the Innate Inflammatory Response
Huizhi Wang et al.
JOURNAL OF IMMUNOLOGY (2011)
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
A. M. Martelli et al.
LEUKEMIA (2011)
Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer
J-S Zhang et al.
ONCOGENE (2011)
Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation
Sejeong Shin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
In vivoactivity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
PA Lee et al.
CANCER RESEARCH (2010)
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2010)
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A
Felix Hernandez et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Emily L. Deer et al.
PANCREAS (2010)
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Jennifer P. Morton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
Jia Luo
CANCER LETTERS (2009)
The role of glycogen synthase kinase 3β in the transformation of epidermal cells
Cuiling Ma et al.
CANCER RESEARCH (2007)
Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice
Yu Wang et al.
CANCER RESEARCH (2006)
Glycogen synthase kinase-3 - An overview of an over-achieving protein kinase
Lisa Kockeritz et al.
CURRENT DRUG TARGETS (2006)
Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer:: Association with kinase activity and tumor dedifferentiation
Andrei V. Ougolkov et al.
CLINICAL CANCER RESEARCH (2006)
Deregulated GSK3β activity in colorectal cancer:: Its association with tumor cell survival and proliferation
A Shakoori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells
AV Ougolkov et al.
CANCER RESEARCH (2005)
Glycogen synthase kinase-3 is an endogenous inhibitor of snail transcription: implications for the epithelial-mesenchymal transition
RE Bachelder et al.
JOURNAL OF CELL BIOLOGY (2005)
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
XJ Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
